Sativex Cancer Drug Trial Poses Barrier to CBD in Supplements

By Josh Long Natural Products Insider

In reliance on a drug trial that was announced eight years ago, FDA has determined CBD cannot be marketed as a dietary supplement.

FDA could change its mind, but only if it is provided evidence that CBD was marketed as a supplement or conventional food before GW Pharmaceuticals plc announced that a clinical trial had been initiated in the United States to study Sativex, a drug that was used to treat pain in patients who suffered from advanced cancer. The drug is composed mostly of two cannabinoids: CBD and THC, the psychoactive ingredient in marijuana.